These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 29789972)

  • 1. Recurrence of Pancreatic Neuroendocrine Tumors and Survival Predicted by Ki67.
    Genç CG; Falconi M; Partelli S; Muffatti F; van Eeden S; Doglioni C; Klümpen HJ; van Eijck CHJ; Nieveen van Dijkum EJM
    Ann Surg Oncol; 2018 Aug; 25(8):2467-2474. PubMed ID: 29789972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for short recurrence-free survival after resection of pancreatic neuroendocrine tumor (PanNET) liver metastases: which patients should undergo resection?
    Masui T; Nagai K; Anazawa T; Kasai Y; Sato A; Nakano K; Uchida Y; Yogo A; Kawaguchi Y; Takaori K; Uemoto S
    Scand J Gastroenterol; 2020 Apr; 55(4):479-484. PubMed ID: 32223573
    [No Abstract]   [Full Text] [Related]  

  • 3. ASO Author Reflections: Pancreatic Neuroendocrine Tumor Recurrence and Survival Predicted by Ki67.
    Nieveen van Dijkum EJM
    Ann Surg Oncol; 2019 Dec; 26(Suppl 3):531-532. PubMed ID: 30519760
    [No Abstract]   [Full Text] [Related]  

  • 4. Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections.
    Boninsegna L; Panzuto F; Partelli S; Capelli P; Delle Fave G; Bettini R; Pederzoli P; Scarpa A; Falconi M
    Eur J Cancer; 2012 Jul; 48(11):1608-15. PubMed ID: 22129889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The size of well differentiated pancreatic neuroendocrine tumors correlates with Ki67 proliferative index and is not associated with age.
    Partelli S; Muffatti F; Rancoita PMV; Andreasi V; Balzano G; Crippa S; Doglioni C; Rubini C; Zamboni G; Falconi M
    Dig Liver Dis; 2019 May; 51(5):735-740. PubMed ID: 30723019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics, Treatment, Outcomes, and Survival in Neuroendocrine G1 and G2 Pancreatic Tumors: Experiences From a Single Tertiary Referral Center.
    Calissendorff J; Bjellerup-Calissendorff F; Bränström R; Juhlin CC; Falhammar H
    Front Endocrinol (Lausanne); 2021; 12():657698. PubMed ID: 33927695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.
    Tsutsumi K; Ohtsuka T; Fujino M; Nakashima H; Aishima S; Ueda J; Takahata S; Nakamura M; Oda Y; Tanaka M
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):418-25. PubMed ID: 24142395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The conundrum of < 2-cm pancreatic neuroendocrine tumors: A preoperative risk score to predict lymph node metastases and guide surgical management.
    Lopez-Aguiar AG; Ethun CG; Zaidi MY; Rocha FG; Poultsides GA; Dillhoff M; Fields RC; Idrees K; Cho CS; Abbott DE; Cardona K; Maithel SK
    Surgery; 2019 Jul; 166(1):15-21. PubMed ID: 31072670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological characteristics and risk factors for recurrence of well-differentiated pancreatic neuroendocrine tumors after radical surgery: a case-control study.
    Zhang P; Li YL; Qiu XD; Luo J; Shi YF; Sun YL; Su F; Qi ZR; Tan HY
    World J Surg Oncol; 2019 Apr; 17(1):66. PubMed ID: 30975157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel Validated Recurrence Risk Score to Guide a Pragmatic Surveillance Strategy After Resection of Pancreatic Neuroendocrine Tumors: An International Study of 1006 Patients.
    Zaidi MY; Lopez-Aguiar AG; Switchenko JM; Lipscomb J; Andreasi V; Partelli S; Gamboa AC; Lee RM; Poultsides GA; Dillhoff M; Rocha FG; Idrees K; Cho CS; Weber SM; Fields RC; Staley CA; Falconi M; Maithel SK
    Ann Surg; 2019 Sep; 270(3):422-433. PubMed ID: 31283562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Redefining the Ki-67 Index Stratification for Low-Grade Pancreatic Neuroendocrine Tumors: Improving Its Prognostic Value for Recurrence of Disease.
    Lopez-Aguiar AG; Ethun CG; Postlewait LM; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Sarmiento JM; Kooby DA; Staley CA; Maithel SK; Cardona K
    Ann Surg Oncol; 2018 Jan; 25(1):290-298. PubMed ID: 29079920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Impact of Phosphohistone-H3-Assisted Mitotic Count and Ki67 Score in the Determination of Tumor Grade and Prediction of Distant Metastasis in Well-Differentiated Pancreatic Neuroendocrine Tumors.
    Ozturk Sari S; Taskin OC; Gundogdu G; Yegen G; Onder S; Keskin M; Saglam S; Ozluk Y; Gulluoglu M; Mete O
    Endocr Pathol; 2016 Jun; 27(2):162-70. PubMed ID: 26936845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining the Role of Lymphadenectomy for Pancreatic Neuroendocrine Tumors: An Eight-Institution Study of 695 Patients from the US Neuroendocrine Tumor Study Group.
    Lopez-Aguiar AG; Zaidi MY; Beal EW; Dillhoff M; Cannon JGD; Poultsides GA; Kanji ZS; Rocha FG; Marincola Smith P; Idrees K; Beems M; Cho CS; Fisher AV; Weber SM; Krasnick BA; Fields RC; Cardona K; Maithel SK
    Ann Surg Oncol; 2019 Aug; 26(8):2517-2524. PubMed ID: 31004295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surgical management of advanced pancreatic neuroendocrine tumors: short-term and long-term results from an international multi-institutional study.
    Birnbaum DJ; Turrini O; Vigano L; Russolillo N; Autret A; Moutardier V; Capussotti L; Le Treut YP; Delpero JR; Hardwigsen J
    Ann Surg Oncol; 2015 Mar; 22(3):1000-7. PubMed ID: 25190116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD47 expression and CD163
    Imam R; Chang Q; Black M; Yu C; Cao W
    BMC Cancer; 2021 Mar; 21(1):320. PubMed ID: 33765961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basing treatment strategy for non-functional pancreatic neuroendocrine tumors on tumor size.
    Kishi Y; Shimada K; Nara S; Esaki M; Hiraoka N; Kosuge T
    Ann Surg Oncol; 2014 Sep; 21(9):2882-8. PubMed ID: 24740828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of recurrence after resection of well-differentiated non-functioning pancreatic neuroendocrine tumors.
    Tan QQ; Wang X; Yang L; Chen YH; Tan CL; Zhu XM; Ke NW; Liu XB
    Medicine (Baltimore); 2020 Jun; 99(24):e20324. PubMed ID: 32541455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascularity and Tumor Size are Significant Predictors for Recurrence after Resection of a Pancreatic Neuroendocrine Tumor.
    Yamamoto Y; Okamura Y; Uemura S; Sugiura T; Ito T; Ashida R; Kato Y; Ohgi K; Yamada M; Sasaki K; Aramaki T; Uesaka K
    Ann Surg Oncol; 2017 Aug; 24(8):2363-2370. PubMed ID: 28271173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lesion-by-lesion correlation between uptake at FDG PET and the Ki67 proliferation index in resected pancreatic neuroendocrine tumors.
    de Mestier L; Armani M; Cros J; Hentic O; Rebours V; Cadiot G; Sauvanet A; Couvelard A; Lebtahi R; Ruszniewski P
    Dig Liver Dis; 2019 Dec; 51(12):1720-1724. PubMed ID: 31350186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Grading of well-differentiated pancreatic neuroendocrine tumors is improved by the inclusion of both Ki67 proliferative index and mitotic rate.
    McCall CM; Shi C; Cornish TC; Klimstra DS; Tang LH; Basturk O; Mun LJ; Ellison TA; Wolfgang CL; Choti MA; Schulick RD; Edil BH; Hruban RH
    Am J Surg Pathol; 2013 Nov; 37(11):1671-7. PubMed ID: 24121170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.